From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:2p3b.gif|left|200px]] | + | {{Seed}} |
| | + | [[Image:2p3b.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_2p3b| PDB=2p3b | SCENE= }} | | {{STRUCTURE_2p3b| PDB=2p3b | SCENE= }} |
| | | | |
| - | '''Crystal Structure of the subtype B wild type HIV protease complexed with TL-3 inhibitor'''
| + | ===Crystal Structure of the subtype B wild type HIV protease complexed with TL-3 inhibitor=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | Although a majority of HIV-1 infections in Brazil are caused by the subtype B virus (also prevalent in the United States and Western Europe), viral subtypes F and C are also found very frequently. Genomic differences between the subtypes give rise to sequence variations in the encoded proteins, including the HIV-1 protease. The current anti-HIV drugs have been developed primarily against subtype B and the effects arising from the combination of drug-resistance mutations with the naturally existing polymorphisms in non-B HIV-1 subtypes are only beginning to be elucidated. To gain more insights into the structure and function of different variants of HIV proteases, we have determined a 2.1 A structure of the native subtype F HIV-1 protease (PR) in complex with the protease inhibitor TL-3. We have also solved crystal structures of two multi-drug resistant mutant HIV PRs in complex with TL-3, from subtype B (Bmut) carrying the primary mutations V82A and L90M, and from subtype F (Fmut) carrying the primary mutation V82A plus the secondary mutation M36I, at 1.75 A and 2.8 A resolution, respectively. The proteases Bmut, Fwt and Fmut exhibit sevenfold, threefold, and 54-fold resistance to TL-3, respectively. In addition, the structure of subtype B wild type HIV-PR in complex with TL-3 has been redetermined in space group P6(1), consistent with the other three structures. Our results show that the primary mutation V82A causes the known effect of collapsing the S1/S1' pockets that ultimately lead to the reduced inhibitory effect of TL-3. Our results further indicate that two naturally occurring polymorphic substitutions in subtype F and other non-B HIV proteases, M36I and L89M, may lead to early development of drug resistance in patients infected with non-B HIV subtypes.
| + | The line below this paragraph, {{ABSTRACT_PUBMED_17467738}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 17467738 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_17467738}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 32: |
Line 36: |
| | [[Category: Tl-3 inhibitor]] | | [[Category: Tl-3 inhibitor]] |
| | [[Category: Wild type subtype b hiv protease]] | | [[Category: Wild type subtype b hiv protease]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 12:15:23 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 15:36:42 2008'' |
Revision as of 12:36, 27 July 2008
Template:STRUCTURE 2p3b
Crystal Structure of the subtype B wild type HIV protease complexed with TL-3 inhibitor
Template:ABSTRACT PUBMED 17467738
About this Structure
2P3B is a Protein complex structure of sequences from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
Reference
Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development., Sanches M, Krauchenco S, Martins NH, Gustchina A, Wlodawer A, Polikarpov I, J Mol Biol. 2007 Jun 15;369(4):1029-40. Epub 2007 Mar 24. PMID:17467738
Page seeded by OCA on Sun Jul 27 15:36:42 2008
